Related Experiment Video
Updated: Jun 19, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
U.S. pharmacy policy: a public health perspective on safety and cost
Pauline Vaillancourt Rosenau1, Lincy S Lal, Jay H Glasser
1Division of Management, Policy, and Community Health, School of Public Health, University of Texas, Houston, Texas 77030, USA. pauline.rosenau@uth.tmc.edu
Abstract:
A public health perspective based on social justice and a population health point of view emphasizes pharmacy policy innovations regarding safety and costs. Such policies that effectively reduce costs include controlling profits, establishing profit targets, extending prescription providers, revising prescription classification schemes, emphasizing generic medications, and establishing formularies. Public education and universal programs may reduce costs, but co-pays and "cost-sharing" do not. Switching medications to over-the-counter (OTC) status, pill splitting, and importing medication from abroad are poor substitutes for authentic public health pharmacy policy. Where policy changes yield savings, public health insists that these savings should be used to increase access and improve population health. In the future, pharmacy policies may emphasize public health accountability more than individual liberty because of potential cost savings to society. Fear of litigation, as an informal mechanism of focusing manufacturer's attention on safety, is inefficient; public health pharmacy policy regarding safety looks toward a more active regulatory role on the part of government. A case study of direct-to-consumer advertising illustrates the complexity of public health pharmacy policy.
Related Concept Videos
Pharmaceutical Poisoning: Potential Scenarios
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Regulation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug Products: Biologics, Biosimilars and Interchangeables

